anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The diagnosis of osteoarthritis (OA) is based on radiological changes that are delayed, along with clinical symptoms. Early and very early diagnosis at the stage of molecular pathology may eventually offer an opportunity for early therapeutic intervention that may retard and prevent future damage. Cartilage oligomeric matrix protein (COMP) is a non-collagenous extracellular matrix protein that promotes the secretion and aggregation of collagen and contributes to the stability of the extracellular matrix. There are contradictory literature data and currently, the parameter is used only for scientific purposes and its significance is not well-determined. The serum level of COMP in patients with metabolic type OA of the knee has not been evaluated. The aim of the study was to analyze serum COMP levels in metabolic knee OA and controls with different BMI. Our results showed that the mean COMP values were significantly higher in the control group (1518.69 ± 232.76 ng/mL) compared to the knee OA patients (1294.58 ± 360.77 ng/mL) (p = 0.0012). This may be related to the smaller cartilage volume in OA patients. Additionally, COMP levels negatively correlated with disease duration (p = 0.04). The COMP level in knee OA with BMI below 30 kg/m2 (n = 61, 1304.50 ± 350.60 ng/mL) was higher compared to cases with BMI ≥ 30 kg/m2 (n = 76, 1286.63 ± 370.86 ng/mL), but the difference was not significant (p = 0.68). Whether this finding is related to specific features in the evolution of the metabolic type of knee OA remains to be determined. Interestingly, comparison of COMP levels in the controls with different BMI revealed significantly higher values in overweight and obese individuals (1618.36 ± 203.76 ng/mL in controls with BMI ≥ 25 kg/m2, n = 18, 1406.61 ± 216.41 ng/mL, n = 16; p = 0.0092). Whether this finding is associated with increased expression of COMP in the adipose tissue or with more intensive cartilage metabolism in relation to higher biomechanical overload in obese patients, considering the earlier development of metabolic type knee OA as an isolated finding, remains to be determined.
The excellent survival rate of cutaneous squamous cell carcinoma (cSCC) exceeding 90% is reduced by the presence of nodal metastases by over 50%. We analysed various risk parameters of cSCC to predict the incidence of nodal metastases. A total of 118 patients with the head cSCC were included in a single-institution retrospective study covering the period from 2008 to 2020. Tumour recurrence, temple location, and tumour infiltration depth were found to be independent predictors of nodal metastases (increasing the probability of metastases by 8.0, 8.1, and 4.3 times, respectively). Furthermore, univariate analysis shows that the tumour size and T stage are significant factors increasing the risk of metastases. Several independent risk factors for the development of metastases in the head cSCC have been confirmed. These findings might help identify at-risk patients who require additional attention for adequate radical treatment and close follow-up. In contrast, elective treatment of lymph nodes is not recommended due to the low incidence of regional metastases.
The present invention relates to a method for predicting Kawasaki disease symptoms by using a HMGB1 gene polymorphism. Kawasaki disease is an acute febrile rash that occurs primarily in infants and toddlers younger than 5 years old and can cause the formation of coronary artery lesions when not treated with the proper use of intravenous immunoglobulin (IVIG). However, patients with Kawasaki disease show resistance to IVIG in many cases, making treatment difficult. A method for predicting Kawasaki disease symptoms by using a HMGB1 gene polymorphism, of the present invention, determines the correlation between the HMGB1 gene and Kawasaki disease symptoms and enables the possibility of coronary artery lesion formation or the possibility of IVIG resistance in patients with Kawasaki disease to be predicted in advance, and thus is expected to be widely used in the medical field. In addition, the present invention relates to a method for predicting the onset of Kawasaki disease by using ITPKC and SLC11A1 gene polymorphisms. Kawasaki disease is an acute febrile rash occuring primarily in infants and toddlers younger than 5 years old and can cause the formation of coronary artery lesions, and Kawasaki disease is known to be the most common cause of acquired heart disease in developed countries. However, until now, no specific test for diagnosing Kawasaki disease has existed such that diagnosis thereof has only been made according to clinical criteria, and thus management is achieved only by post-treatment and not by prevention. A method for predicting the onset of Kawasaki disease by using ITPKC and SLC11A1 gene polymorphisms, of the present invention, is applied to the correlation, specified in Koreans, between ITPKC and SLC11A1 genes and to synergistic effects thereby in the onset of Kawasaki disease, and enables possibility of onset to be predicted before the onset of Kawasaki disease, and thus is expected to be widely used in the medical field.
PURPOSE: In the last decades, there has been a refinement in total hip arthroplasty, which allowed surgeons to achieve the highest performance and better patient outcomes. Preoperative planning in primary hip arthroplasty is an essential step that guides the surgeon in restoring the anatomy and biomechanics of the joint. This study aims to evaluate the accuracy of the 2D digital planning, considering cup sizing, stem sizing, and limb length discrepancy. Additionally, we conducted a multivariable analysis of demographic data and comorbidities to find factors influencing preoperative planning.
METHODS: This retrospective study analyzed the planning accuracy in 800 consecutive uncemented primary total hip arthroplasty. We compared the preoperatively planned total hip arthroplasty with postoperative results regarding the planned component size, the implanted size, and the lower limb length restoration. Therefore, we investigated factors influencing planning accuracy: overweight and obesity, sex, age, past medical history, comorbidities, and implant design. All the surgeries were performed in the posterolateral approach by one expert surgeon who did the preoperative planning. The preoperative planning was determined to be (a) exact if the planned and the implanted components were the same size and (b) accurate if exact ± one size. The restoration of postoperative limb length discrepancy was classified into three groups: ± 3 mm, ± 5 mm, and ± 10 mm. This assessment was performed through a digital method 2D based on a standard hip X-ray.
RESULTS: This court of 800 implants showed that planning was exact in 60% of the cups and 44% of the stems and was accurate in 94% of the cups and 80% of the stems. The postoperative limb length discrepancy was ± 3 mm in 91% and ± 5 mm in 97%.
CONCLUSIONS: This study showed preoperative 2D digital planning great precision and reliability, and we demonstrated that it was accurate in 94% of the cups and 80% of the stems. Therefore, the preoperative limb length discrepancy analysis was essential to guarantee the recovery of the operated limb's correct length.
Use of a medicament for the treatment of hepatic encephalopathy is claimed. The medicament contains branched chain amino acids in the form of their salts in a pharmaceutical formulation that resists stomach acid. Pref. the hydrochloride salts are used. The aminoacids are valine, leucine and/or isoleucine. The formulation is a controlled release form.
Teratogenic Effects

Pregnancy Category C

In teratology studies, isolated occurrences of alterations in limb development were found and included polydactyly, oligodactyly, syndactyly, and unossified phalanges in rats and oligodactyly and synostosis of metatarsals in rabbits. These were observed at dose levels (2 to 14 mg/kg/day) close to human clinical doses. However, the frequency and the dosage group distribution of these findings in initial or repeated studies did not establish a clear drug or dose-response relationship. Animal reproduction studies are not always predictive of human response. There are no adequate and well- controlled studies in pregnant women. Etodolac capsules and tablets should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
ABSTRACT This invention relates to certain bicyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. ????-Lactamases hydrolyze ????-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with ????-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of general formula I or a pharmaceutically acceptable salt or in vivo hydrolyzable ester R<sub>5</sub> thereof: Formula (I) wherein: One of A and B denotes hydrogen and the other an optionally substituted fused bicyclic heteroaryl group; and X=O or S.
MTX/6MP maintenance therapy is challenged by treatment related liver toxicity, failure to achieve the target treatment parameter in all patients, and lack of direct parameters for monitoring treatment efficacy or even intensity. Patients with low activity of thiopurine methyltransferase (TPMT), an enzyme involved in the metabolism of 6MP, have lower levels of liver toxic metabolites (MeMPs), higher levels of the major active metabolites (TGNs), and reduced relapse rates. Most patients (90%) have high TPMT activity. Nearly all patients with high TPMT activity and high MeMP levels experience elevated liver enzymes. Increasing the 6MP dose in patients with high TPMT activity, to intensify therapy, will mainly lead to further increase in the MeMP level. A novel approach compensating the adverse thiopurine metabolism of the majority of patients is warranted.
People uses cosmetic products to make the peoples skin in an optimal state. However, the state of peoples skin changes as seasons change. Accordingly, it is unsuitable that people use the same cosmetic product for the peoples skin in all seasons. Nevertheless, people can hardly discard the remainder of a cosmetic product for the peoples skin four times a year. Accordingly, a cosmetic product is manufactured using capsules whose forms are changed according to seasonal changes, and which are included in the cosmetic product. The capsules burst and melt in autumn and winter, thereby releasing ceramide or the like which enhances moisturizing ability. Meanwhile, capsules are re-formed in spring and summer, thereby fully absorbing ceramide or the like.
The invention provides a traditional Chinese medicine composition for treating wind-cold type common cold. The composition is prepared from the following raw materials, by weight, 6-10 parts of radix bupleuri, 8-10 parts of scutellaria baicalensis, 6-10 parts of rhizoma pinelliae, 5-8 parts of licorice, 6-9 parts of fresh ginger, 8-10 parts of fructus ziziphi jujubae, 8-10 parts of schizonepeta, 6-10 parts of saposhnikovia divaricata and 6-10 parts of magnolia flowers. The preparations of the composition can be capsules, granules, tablets, mixtures, syrups and the like. The traditional Chinese medicine composition is especially effective on wind-cold type common cold, analyzes pathogenesis deeply and acts appropriately to the situation. The composition has remarkable curative effects on runny nose, stuffy nose, headache, no fever or slight fever symptoms. The composition has minimal toxic and side effects and good safety, can be accepted by patients easily, contains fewer ingredients, and is convenient for preparation and low-cost.
PURPOSE: An antioxidative composition and an active oxygen removing device using the same are provided to reduce or remove active oxygen generated from the human body. CONSTITUTION: An active oxygen removing device comprises a main body(10), a fixing member(20), and an antioxidative part. The main body comprises a housing and a cover. In the back of the housing, a receiving part having a space is prepared. The cover is combined with the housing, is placed adjacent to the face of a user, and is able to be fixed to the housing by using a fastener. An antioxidative composition delivers phytochemical to a part of the human body.
The invention provides a cell biological drug and a biological preparation for allogeneic adoptive cellular immunotherapy of blood system diseases such as MDS (myelodysplastic syndromes) or leukemia, and a preparation method. The preparation method of the cell biological drug consists of: subjecting an immune cell and an antigen to co-culture in a liquid cell culture medium in a culture container so as to obtain a specific immune cell culture resisting the corresponding antigen; and separating a cell biological drug with an immune response from the obtained culture. The immune cell can be an allogeneic cell, has no allogeneic rejection reaction in use, and has high security. After treatment of MDS, hematopoietic functions in bone marrow puncture, bone marrow biopsy and bone marrow stem cell culture are all significantly improved. In a treatment process, patients have good tolerance. In the invention, MDS is treated by means of a brand new etiological treatment strategy of improving organism immunity, and the hematopoietic function in patients is effectively restored. The cell biological drug provided in the invention has good prospects for treatment of other hematopoietic stem cell malignant cloning diseases including leukemia.
A controlled-release drug delivery system advantageously includes an open-ended, inflexible sleeve, at least two controlled-release layers and two open-center caps. Each controlled-release layer abuts a sealing surface that is located within and near each end of the sleeve. The caps seal each controlled-release layer against the abutting sealing surface. One or more dose units of drug are disposed in a region that is formed between the controlled-release layers. The controlled-release layers dissolve, at a predetermined rate, by the action of body fluids that are in contact with those layers through the center of the caps. Release of drug is delayed at least until the controlled-release layers dissolve. The dose unit itself, which is advantageously a core, can be tailored to provide an extended period of drug release. One or more dose units that provide an immediate release component can also be disposed near each end of the sleeve.
Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.
Liver fibrosis is a chronic pathological condition lacking specific clinical treatments. Stem cells, with notable potential in regenerative medicine, offer promise in treating liver fibrosis. However, stem cell therapy is hindered by potential immunological rejection, carcinogenesis risk, efficacy variation, and high cost. Stem cell secretome-based cell-free therapy offers potential solutions to address these challenges, but it is limited by low delivery efficiency and rapid clearance. Herein, an innovative approach for in situ implantation of smart microneedle (MN) arrays enabling precisely controlled delivery of multiple therapeutic agents directly into fibrotic liver tissues is developed. By integrating cell-free and platinum-based nanocatalytic combination therapy, the MN arrays can deactivate hepatic stellate cells. Moreover, they promote excessive extracellular matrix degradation by more than 75%, approaching normal levels. Additionally, the smart MN arrays can provide hepatocyte protection while reducing inflammation levels by ≈70-90%. They can also exhibit remarkable capability in scavenging almost 100% of reactive oxygen species and alleviating hypoxia. Ultimately, this treatment strategy can effectively restrain fibrosis progression. The comprehensive in vitro and in vivo experiments, supplemented by proteome and transcriptome analyses, substantiate the effectiveness of the approach in treating liver fibrosis, holding immense promise for clinical applications.
Participants receive BL-B16D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Therapeutic doses of hydroxyzine seldom produce impairment of mental alertness. However, drowsiness may occur; if so, it is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Dryness of the mouth may be encountered at higher doses. Extensive clinical use has substantiated the absence of toxic effects on the liver or bone marrow when administered in the recommended doses for over four years of uninterrupted therapy. The absence of adverse effects has been further demonstrated in experimental studies in which excessively high doses were administered.

Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Continuous therapy with over one gram per day has been employed in some patients without these effects having been encountered. Hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) in post marketing reports.
This group of patients will be treated with single intra-articular injection of Homologous PRP. At the 6-month follow-up visit, the patient will be informed about the treatment received.
The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
Black raspberry powder 25 grams once daily for 4 weeks. If tolerated, will increase to 25 grams twice a day for another 20 weeks. Total length of active treatment 24 weeks.
The present invention extracts Xinjiang Poacynum hendersonii (Hook. F.) Woodson as material through conventional extraction process and chromatographic silicon gel separation to obtain 11 compounds. The compounds includes isoquercitrin, which is the main components of Poacynum hendersonii (Hook. F.) Woodson, accounts for 0.2 % and is main blood pressure lowering and blood fat lowering component; and one lignan compound, which has antiphlogistic and tumor cell activity resisting effects, accounts for 0.05 %, and structure similar to that of the blood pressure lowering active component in Chinese medicine material eucommia bark. These two compounds may be used as the mark compounds for qualitatively and quantitatively measurement of the medicine material and as the functional index components for developing health articles and medicines of Poacynum hendersonii (Hook. F.) Woodson.
The invention discloses the grape dashing enzyme ramification dealing with the blood platelet assembling and the thrombin active ability and the producing process belonging to the domain of the gene engineering and the producing art of the biology dissolving bolt medicament. The nucleotide acid serial of the grape dashing enzyme ramification restraining the blood platelet assembling and the thrombin active ability is disclosed. The producing process fuses the RGD series, the C end series of the hirudin and the constructed low antigen and high active ability SAK breaking body gene using the gene recombining technology outer the body, at the same time, the Xa gene incising location point and the flexible connecting arm and it's C end amino acid is decorated, the another amino acid is appended. The fusing albumen expressing carrier is constructed to gain the efficient expressed recombining SAK ramification using the double enzyme chipping and the PCR appraising alkalescence of the constructed breaking body. The ramification has the function of restraining the blood platelet assembling and interdicting the thrombin active ability and establishes the base of developing the new generation dissolving bolt medication. So the applied range of the new SAK ramification is expanded largely.